Abstract
In recurrent malignant gliomas, we scheduled a protocol by adding to systemic temozolomide a local treatment delivered through a reservoire positioned in the surgically created cavity, consisting of either mitoxantrone, liposome-loaded doxorubicine or nimustine (ACNU). The progression-free survival (PFS) and survival time (ST) of the whole group of 112 patients were 8.3 and 11 months, respectively, in GBM patients, and 14 and 18 months in AA patients. To limit the selection bias in recruitment we matched locally treated patients with the whole group of patients treated for 3 years and having undergone the same protocol with the exception of local drug delivery. Variables such as age, histology and local chemotherapy delivery were proved to be statistically significant independent factors on adjunctive PFS and ST. Another group of 12 recurrent malignant gliomas with further progression was locally managed according to convection-enhanced delivery (CED) of mitoxantrone; the preliminary results show good tolerability of the schedule.
| Original language | English |
|---|---|
| Journal | Neurological Sciences |
| Volume | 26 |
| Issue number | SUPPL. 1 |
| DOIs | |
| Publication status | Published - May 2005 |
Fingerprint
Keywords
- Doxorubicine
- Glioblastoma
- Loco-regional chemotherapy
- Nimustine
ASJC Scopus subject areas
- Neuroscience(all)
- Clinical Neurology
Cite this
Local drug delivery in recurrent malignant gliomas. / Boiardi, A.; Eoli, M.; Salmaggi, A.; Lamperti, E.; Botturi, A.; Solari, A.; Di Meco, F.; Broggi, G.; Silvani, A.
In: Neurological Sciences, Vol. 26, No. SUPPL. 1, 05.2005.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Local drug delivery in recurrent malignant gliomas
AU - Boiardi, A.
AU - Eoli, M.
AU - Salmaggi, A.
AU - Lamperti, E.
AU - Botturi, A.
AU - Solari, A.
AU - Di Meco, F.
AU - Broggi, G.
AU - Silvani, A.
PY - 2005/5
Y1 - 2005/5
N2 - In recurrent malignant gliomas, we scheduled a protocol by adding to systemic temozolomide a local treatment delivered through a reservoire positioned in the surgically created cavity, consisting of either mitoxantrone, liposome-loaded doxorubicine or nimustine (ACNU). The progression-free survival (PFS) and survival time (ST) of the whole group of 112 patients were 8.3 and 11 months, respectively, in GBM patients, and 14 and 18 months in AA patients. To limit the selection bias in recruitment we matched locally treated patients with the whole group of patients treated for 3 years and having undergone the same protocol with the exception of local drug delivery. Variables such as age, histology and local chemotherapy delivery were proved to be statistically significant independent factors on adjunctive PFS and ST. Another group of 12 recurrent malignant gliomas with further progression was locally managed according to convection-enhanced delivery (CED) of mitoxantrone; the preliminary results show good tolerability of the schedule.
AB - In recurrent malignant gliomas, we scheduled a protocol by adding to systemic temozolomide a local treatment delivered through a reservoire positioned in the surgically created cavity, consisting of either mitoxantrone, liposome-loaded doxorubicine or nimustine (ACNU). The progression-free survival (PFS) and survival time (ST) of the whole group of 112 patients were 8.3 and 11 months, respectively, in GBM patients, and 14 and 18 months in AA patients. To limit the selection bias in recruitment we matched locally treated patients with the whole group of patients treated for 3 years and having undergone the same protocol with the exception of local drug delivery. Variables such as age, histology and local chemotherapy delivery were proved to be statistically significant independent factors on adjunctive PFS and ST. Another group of 12 recurrent malignant gliomas with further progression was locally managed according to convection-enhanced delivery (CED) of mitoxantrone; the preliminary results show good tolerability of the schedule.
KW - Doxorubicine
KW - Glioblastoma
KW - Loco-regional chemotherapy
KW - Nimustine
UR - http://www.scopus.com/inward/record.url?scp=18344367863&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=18344367863&partnerID=8YFLogxK
U2 - 10.1007/s10072-005-0403-z
DO - 10.1007/s10072-005-0403-z
M3 - Article
C2 - 15883691
AN - SCOPUS:18344367863
VL - 26
JO - Neurological Sciences
JF - Neurological Sciences
SN - 1590-1874
IS - SUPPL. 1
ER -